IMVARIA is a health tech company pioneering AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease and reduce the need for invasive biopsy testing. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its AI Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. IMVARIA is based in Berkeley, CA.

IMVARIA brings artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases. Their innovative AI biomarkers provide unique insights into diagnosis and disease assessment, driven by AI and high-quality clinical data. The company aims to empower physicians with precise digital biomarker technology to take on the greatest challenges in serious and rare diseases, helping clinicians make better-informed decisions and optimize patient outcomes.

IMVARIA has developed FDA-authorized AI tools such as Fibresolve and ScreenDx, which assist clinicians in the non-invasive diagnosis and assessment of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). These tools use AI to analyze lung CT imaging data and provide adjunctive diagnostic information to support clinical decision-making. IMVARIA's solutions are designed to be supplementary to current standard-of-care workflows, accessible to qualified clinicians.

The company has entered into a know-how agreement with Mayo Clinic to advance AI digital biomarker development for cancer analysis, starting with lung cancer. They also have a strategic distribution partnership with Medical Horizons to expand their presence in the Middle East and North Africa (MENA) region.

IMVARIA is a remote-first company with a strong clinical and technical founding team. They are actively growing their engineering and commercial teams to build and deploy their medical-grade AI platform. Job listings can be found on Wellfound.